We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » FDA’s New Biosimilars Plan - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - Nov. 7, 2018

$287.00

Audio Recording/Transcript - Nov. 7, 2018

$258.00

Audio Recording/Transcript - Nov. 7, 2018

$244.00

Audio Recording/Transcript - Nov. 7, 2018

$230.00

Audio Recording/Transcript - Nov. 7, 2018

$215.00

FDA’s New Biosimilars Plan - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

FDA’s New Biosimilars Plan: What’s the Deal With the Agency’s New Policy and What’s the Impact on Pharmaceutical Stakeholders

To date 12 biosimilar products have been approved by the FDA — but only 3 have reached the market.

The FDA’s Biosimilars Action Plan:

  • Lays out how the agency is modernizing regulatory policies
  • Accommodates new scientific tools to better enable comparison between biosimilars and reference products
  • Potentially reduces the need for clinical studies

FDAnews has enlisted the help of consultant Nitisha Pyndiah to spell out what you need to know — what the FDA is thinking, where the industry is heading, and how you can gain competitive advantage. Here are just a few of the specifics to be covered:

  • The key elements of the Biosimilars Action Plan — including balancing innovation and competition
  • Interchangeability vs. biosimilarity — understanding the differences under the BPCI Act
  • The development and implementation of new FDA review tools (i.e.: standardized review templates tailored to marketing applications for biosimilar and interchangeable products)
  • Enhancements to the Purple Book, including more information about approved biological products
  • The significance of the BsUFA II fees

You need to understand the FDA’s action plan and how it will affect your biosimilar product development.  Order today to get an insight into the different stakeholders opinion.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing